We read with interest the manuscript “Sensitivity and specificity of surveillance case
definitions in detection of influenza and respiratory syncytial virus among hospitalized …

Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …

We read with interest the article reported by JM Coulson et al. that three cases of COVID-19
rebound were associated with nirmatrelvir/ritonavir pre-hospital therapy. 1 Paxlovid …

Background Paxlovid is recognized as an effective medication in preventing the progression
of coronavirus disease of 2019 (COVID-19) to severe form in adults; however, its efficacy …

The omicron variant of SARS-CoV-2 has been reported in Shanghai, China, since March
2022. In two months, the emergence of the omicron variant has resulted in 600 000 …

Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …

Summary Background Corona Virus Disease 2019 (COVID-19) due to the 2019 novel
coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China …

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment
— California, December 2021–May 2022 | MMWR Skip directly to site content Skip directly to …

According to the WHO, more than 30 million children under five years of age still suffer from
vaccine-preventable diseases (VPDs) every year in Africa. 1 Of these, over half a million die …

Our study is aimed to access the efficacy and safety outcomes for coronavirus disease 2019
(COVID‐19) patients treated with Paxlovid. According to inclusion and exclusion criteria …